This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Mirati Therapeutics, Inc.. Active years: 2017-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2019
Title: The Innovations of Robert Anthony Galemmo, Jr.
Introduction
Robert Anthony Galemmo, Jr. is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit LSD1 activity. With a total of 2 patents, his work is focused on innovative methods for treating cancer.
Latest Patents
Galemmo's latest patents revolve around LSD1 inhibitors. The present invention relates to compounds that inhibit LSD1 activity. In particular, these inventions include pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions developed by Galemmo.
Career Highlights
Galemmo is currently associated with Mirati Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in the ongoing fight against cancer, showcasing his commitment to improving patient outcomes through innovative therapies.
Collaborations
Some of his notable coworkers include Matthew Arnold Marx and Arkadii Vaisburg. Their collaborative efforts contribute to the dynamic research environment at Mirati Therapeutics, Inc.
Conclusion
Robert Anthony Galemmo, Jr. exemplifies the spirit of innovation in the pharmaceutical industry. His contributions to the development of LSD1 inhibitors highlight the importance of research in combating cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile